Levobupivacaine Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global levobupivacaine market is anticipated to grow at a CAGR of 3.9% during the forecast period (2022-2028). The demand for levobupivacaine is expected to rise due to an increase in the number of plastic surgeries and other cosmetic operations. The rising use of dental implants and sedation dentistry, as well as the growing global senior population, are some of the factors that will drive market expansion in the approaching years. In addition, the number of surgeries and treatments requiring local anesthetics, such as orthopedic surgery, is on the rise which is anticipated to contribute to industry growth.

The S-enantiomer of the bupivacaine medication, levobupivacaine, is classed as a local anaesthetic. It is a member of the amino amide family and has become quite popular among anesthesiologists as a local anesthetic medication due to its low cardiotoxicity and motor blockage. It is a long-acting anesthetic that was developed in response to a large increase in the reported incidences of cardiac arrest and seizures related to intravascular bupivacaine injection. In comparison to other anesthetic drugs such as ropivacaine and bupivacaine, it has superior pharmacokinetic qualities such as volume of distribution and rate of clearance, making it safe and effective.

In the clinical application segment for levobupivacaine, epidural anesthesia has the biggest market share. It is the most common type of anesthetic used to alleviate pain during delivery. Peripheral nerve blocks are used to numb the nerves of the body part undergoing surgical procedures, and the anesthetic effect lasts beyond the treatment to provide comfort to the patient. Due to the large increase in traumatic accidents needing prompt surgical treatments to address catastrophic injuries, the market is expected to grow rapidly throughout the projected period.

Some major players in the market includeAbbVie Inc., AstraZeneca PLC, Pfizer Inc., Purdue Pharma L.P., Recipharm AB, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

Company’s Product

Recipharm AB offers levobupivacaine hydrochloride, the sodium channel blocker levobupivacaine hydrochloride is used as a long-acting local anaesthetic for epidural anesthesia. Levobupivacaine is the (S)-isomer of bupivacaine, and it has the same efficacy as bupivacaine but with a lower risk of cardiotoxicity. The action potential and sodium transit in neuronal membranes are blocked by levobupivacaine.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Clinical Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- AbbVie Inc., AstraZeneca PLC, Pfizer Inc., Purdue Pharma L.P., Recipharm AB,among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Levobupivacaine Market Report by Segment

By Clinical Application

• Epidural Anesthesia
• Spinal Anesthesia
• Peripheral Nerve Blocks